#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=This study examined whether the combined administration of 6.0 g of glycine and 0.4 g of tryptophan suppressed the elevation in serum uric acid levels induced by purine ingestion and increased urinary uric acid excretion .
3-1	15-19	This	event[3]	new[3]	coref	9-1[48_3]
3-2	20-25	study	event[3]	new[3]	_	_
3-3	26-34	examined	_	_	_	_
3-4	35-42	whether	_	_	_	_
3-5	43-46	the	organization[4]	new[4]	_	_
3-6	47-55	combined	organization[4]	new[4]	_	_
3-7	56-70	administration	organization[4]	new[4]	_	_
3-8	71-73	of	organization[4]	new[4]	_	_
3-9	74-77	6.0	organization[4]|quantity[5]	new[4]|new[5]	_	_
3-10	78-79	g	organization[4]|quantity[5]	new[4]|new[5]	_	_
3-11	80-82	of	organization[4]|quantity[5]	new[4]|new[5]	_	_
3-12	83-90	glycine	organization[4]|quantity[5]|substance	new[4]|new[5]|new	coref	5-1[24_0]
3-13	91-94	and	_	_	_	_
3-14	95-98	0.4	quantity[7]	new[7]	_	_
3-15	99-100	g	quantity[7]	new[7]	_	_
3-16	101-103	of	quantity[7]	new[7]	_	_
3-17	104-114	tryptophan	quantity[7]|substance	new[7]|new	coref	5-4
3-18	115-125	suppressed	_	_	_	_
3-19	126-129	the	abstract[9]	new[9]	coref	10-15[58_9]
3-20	130-139	elevation	abstract[9]	new[9]	_	_
3-21	140-142	in	abstract[9]	new[9]	_	_
3-22	143-148	serum	abstract[9]|abstract|abstract[13]	new[9]|new|new[13]	coref|coref|coref|coref	10-19|10-18[62_13]|10-19|10-18[62_13]
3-23	149-153	uric	abstract[9]|abstract|abstract[13]	new[9]|new|new[13]	coref	3-33
3-24	154-158	acid	abstract[9]|substance|abstract[13]	new[9]|new|new[13]	coref	3-34
3-25	159-165	levels	abstract[9]|abstract[13]	new[9]|new[13]	_	_
3-26	166-173	induced	_	_	_	_
3-27	174-176	by	_	_	_	_
3-28	177-183	purine	animal|event[15]	new|new[15]	coref|coref|coref|coref	4-7[22_15]|10-25|4-7[22_15]|10-25
3-29	184-193	ingestion	event[15]	new[15]	_	_
3-30	194-197	and	_	_	_	_
3-31	198-207	increased	event	new	none|none	3-31[0_271]|12-8
3-32	208-215	urinary	person|abstract[19]	new|new[19]	coref|coref|coref|coref	12-9|12-9[90_19]|12-9|12-9[90_19]
3-33	216-220	uric	abstract|abstract[19]	giv|new[19]	coref	10-20
3-34	221-225	acid	substance|abstract[19]	giv|new[19]	coref	4-3
3-35	226-235	excretion	abstract[19]	new[19]	_	_
3-36	236-237	.	_	_	_	_

#Text=The amino acid doses used for single ingestion were based on those used in continual supplementation .
4-1	238-241	The	quantity[21]	new[21]	coref	6-5[31_21]
4-2	242-247	amino	quantity[21]	new[21]	_	_
4-3	248-252	acid	substance|quantity[21]	giv|new[21]	coref	10-21
4-4	253-258	doses	quantity[21]	new[21]	_	_
4-5	259-263	used	_	_	_	_
4-6	264-267	for	_	_	_	_
4-7	268-274	single	event[22]	giv[22]	coref	10-25[64_22]
4-8	275-284	ingestion	event[22]	giv[22]	_	_
4-9	285-289	were	_	_	_	_
4-10	290-295	based	_	_	_	_
4-11	296-298	on	_	_	_	_
4-12	299-304	those	_	_	_	_
4-13	305-309	used	_	_	_	_
4-14	310-312	in	_	_	_	_
4-15	313-322	continual	abstract[23]	new[23]	coref	9-10[52_23]
4-16	323-338	supplementation	abstract[23]	new[23]	_	_
4-17	339-340	.	_	_	_	_

#Text=Both glycine and tryptophan are present in dietary proteins that are ingested in normal daily living .
5-1	341-345	Both	substance[24]|substance[25]	giv[24]|new[25]	coref|coref|coref|coref	6-3[30_24]|8-13[45_25]|6-3[30_24]|8-13[45_25]
5-2	346-353	glycine	substance[24]|substance[25]	giv[24]|new[25]	_	_
5-3	354-357	and	substance[25]	new[25]	_	_
5-4	358-368	tryptophan	substance[25]|substance	new[25]|giv	coref	8-15[46_0]
5-5	369-372	are	_	_	_	_
5-6	373-380	present	_	_	_	_
5-7	381-383	in	_	_	_	_
5-8	384-391	dietary	abstract|substance[28]	new|new[28]	coref|coref	11-48|11-48
5-9	392-400	proteins	substance[28]	new[28]	_	_
5-10	401-405	that	_	_	_	_
5-11	406-409	are	_	_	_	_
5-12	410-418	ingested	_	_	_	_
5-13	419-421	in	_	_	_	_
5-14	422-428	normal	abstract[29]	new[29]	_	_
5-15	429-434	daily	abstract[29]	new[29]	_	_
5-16	435-441	living	abstract[29]	new[29]	_	_
5-17	442-443	.	_	_	_	_

#Text=However , glycine at doses of up to 90 g per day administered over several weeks were reported no serious adverse effects .
6-1	444-451	However	_	_	_	_
6-2	452-453	,	_	_	_	_
6-3	454-461	glycine	substance[30]	giv[30]	coref	8-13[0_30]
6-4	462-464	at	substance[30]	giv[30]	_	_
6-5	465-470	doses	substance[30]|quantity[31]	giv[30]|giv[31]	_	_
6-6	471-473	of	substance[30]|quantity[31]	giv[30]|giv[31]	_	_
6-7	474-476	up	substance[30]|quantity[31]	giv[30]|giv[31]	_	_
6-8	477-479	to	substance[30]|quantity[31]	giv[30]|giv[31]	_	_
6-9	480-482	90	substance[30]|quantity[31]|quantity[32]	giv[30]|giv[31]|new[32]	_	_
6-10	483-484	g	substance[30]|quantity[31]|quantity[32]	giv[30]|giv[31]|new[32]	_	_
6-11	485-488	per	substance[30]|quantity[31]|quantity[32]	giv[30]|giv[31]|new[32]	_	_
6-12	489-492	day	substance[30]|quantity[31]|quantity[32]|time	giv[30]|giv[31]|new[32]|new	coref	7-12
6-13	493-505	administered	_	_	_	_
6-14	506-510	over	_	_	_	_
6-15	511-518	several	time[34]	new[34]	_	_
6-16	519-524	weeks	time[34]	new[34]	_	_
6-17	525-529	were	_	_	_	_
6-18	530-538	reported	_	_	_	_
6-19	539-541	no	abstract[35]	new[35]	coref	7-17[40_35]
6-20	542-549	serious	abstract[35]	new[35]	_	_
6-21	550-557	adverse	abstract[35]	new[35]	_	_
6-22	558-565	effects	abstract[35]	new[35]	_	_
6-23	566-567	.	_	_	_	_

#Text=The oral administration of up to 5.0 g of l-tryptophan per day did not lead to any adverse effects in young adult females .
7-1	568-571	The	organization[36]	new[36]	_	_
7-2	572-576	oral	organization[36]	new[36]	_	_
7-3	577-591	administration	organization[36]	new[36]	_	_
7-4	592-594	of	organization[36]	new[36]	_	_
7-5	595-597	up	organization[36]	new[36]	_	_
7-6	598-600	to	organization[36]	new[36]	_	_
7-7	601-604	5.0	organization[36]|quantity[37]	new[36]|new[37]	_	_
7-8	605-606	g	organization[36]|quantity[37]	new[36]|new[37]	_	_
7-9	607-609	of	organization[36]|quantity[37]	new[36]|new[37]	_	_
7-10	610-622	l-tryptophan	organization[36]|quantity[37]|substance[38]	new[36]|new[37]|new[38]	_	_
7-11	623-626	per	organization[36]|quantity[37]|substance[38]	new[36]|new[37]|new[38]	_	_
7-12	627-630	day	organization[36]|quantity[37]|substance[38]|time	new[36]|new[37]|new[38]|giv	_	_
7-13	631-634	did	_	_	_	_
7-14	635-638	not	_	_	_	_
7-15	639-643	lead	_	_	_	_
7-16	644-646	to	_	_	_	_
7-17	647-650	any	abstract[40]	giv[40]	coref	8-3[42_40]
7-18	651-658	adverse	abstract[40]	giv[40]	_	_
7-19	659-666	effects	abstract[40]	giv[40]	_	_
7-20	667-669	in	abstract[40]	giv[40]	_	_
7-21	670-675	young	abstract[40]|person[41]	giv[40]|new[41]	_	_
7-22	676-681	adult	abstract[40]|person[41]	giv[40]|new[41]	_	_
7-23	682-689	females	abstract[40]|person[41]	giv[40]|new[41]	_	_
7-24	690-691	.	_	_	_	_

#Text=Therefore , no adverse effects were attributed to the combined administration of glycine and tryptophan in the current trial .
8-1	692-701	Therefore	_	_	_	_
8-2	702-703	,	_	_	_	_
8-3	704-706	no	abstract[42]	giv[42]	coref	20-21[171_42]
8-4	707-714	adverse	abstract[42]	giv[42]	_	_
8-5	715-722	effects	abstract[42]	giv[42]	_	_
8-6	723-727	were	_	_	_	_
8-7	728-738	attributed	_	_	_	_
8-8	739-741	to	_	_	_	_
8-9	742-745	the	organization[43]	new[43]	_	_
8-10	746-754	combined	organization[43]	new[43]	_	_
8-11	755-769	administration	organization[43]	new[43]	_	_
8-12	770-772	of	organization[43]	new[43]	_	_
8-13	773-780	glycine	organization[43]|substance|substance[45]	new[43]|giv|giv[45]	coref|coref	10-10|10-10
8-14	781-784	and	organization[43]|substance[45]	new[43]|giv[45]	_	_
8-15	785-795	tryptophan	organization[43]|substance[45]|substance[46]	new[43]|giv[45]|giv[46]	coref	9-10[0_46]
8-16	796-798	in	organization[43]|substance[45]|substance[46]	new[43]|giv[45]|giv[46]	_	_
8-17	799-802	the	organization[43]|substance[45]|substance[46]|event[47]	new[43]|giv[45]|giv[46]|new[47]	_	_
8-18	803-810	current	organization[43]|substance[45]|substance[46]|event[47]	new[43]|giv[45]|giv[46]|new[47]	_	_
8-19	811-816	trial	organization[43]|substance[45]|substance[46]|event[47]	new[43]|giv[45]|giv[46]|new[47]	_	_
8-20	817-818	.	_	_	_	_

#Text=This study confirmed the safety of combined glycine and tryptophan supplementation .
9-1	819-823	This	event[48]	giv[48]	coref	10-1[53_48]
9-2	824-829	study	event[48]	giv[48]	_	_
9-3	830-839	confirmed	_	_	_	_
9-4	840-843	the	abstract[49]	new[49]	_	_
9-5	844-850	safety	abstract[49]	new[49]	_	_
9-6	851-853	of	abstract[49]	new[49]	_	_
9-7	854-862	combined	abstract[49]|substance[50]	new[49]|new[50]	_	_
9-8	863-870	glycine	abstract[49]|substance[50]	new[49]|new[50]	_	_
9-9	871-874	and	abstract[49]	new[49]	_	_
9-10	875-885	tryptophan	abstract[49]|substance|abstract[52]	new[49]|giv|giv[52]	coref|coref|coref|coref	10-12|13-6[96_52]|10-12|13-6[96_52]
9-11	886-901	supplementation	abstract[49]|abstract[52]	new[49]|giv[52]	_	_
9-12	902-903	.	_	_	_	_

#Text=The current study demonstrated that the combined administration of glycine and tryptophan significantly suppressed the elevation in the serum uric acid levels caused by purine ingestion in healthy subjects .
10-1	904-907	The	event[53]	giv[53]	coref	12-18[94_53]
10-2	908-915	current	event[53]	giv[53]	_	_
10-3	916-921	study	event[53]	giv[53]	_	_
10-4	922-934	demonstrated	_	_	_	_
10-5	935-939	that	_	_	_	_
10-6	940-943	the	organization[54]	new[54]	coref	11-4[69_54]
10-7	944-952	combined	organization[54]	new[54]	_	_
10-8	953-967	administration	organization[54]	new[54]	_	_
10-9	968-970	of	organization[54]	new[54]	_	_
10-10	971-978	glycine	organization[54]|substance|substance[56]	new[54]|giv|new[56]	coref|coref|coref|coref	11-16|13-9[98_56]|11-16|13-9[98_56]
10-11	979-982	and	organization[54]|substance[56]	new[54]|new[56]	_	_
10-12	983-993	tryptophan	organization[54]|substance[56]|substance	new[54]|new[56]|giv	coref	11-26
10-13	994-1007	significantly	_	_	_	_
10-14	1008-1018	suppressed	_	_	_	_
10-15	1019-1022	the	abstract[58]	giv[58]	coref	11-36[76_58]
10-16	1023-1032	elevation	abstract[58]	giv[58]	_	_
10-17	1033-1035	in	abstract[58]	giv[58]	_	_
10-18	1036-1039	the	abstract[58]|abstract[62]	giv[58]|giv[62]	coref	11-39[80_62]
10-19	1040-1045	serum	abstract[58]|abstract|abstract[62]	giv[58]|giv|giv[62]	coref	11-40
10-20	1046-1050	uric	abstract[58]|abstract|abstract[62]	giv[58]|giv|giv[62]	coref	11-41
10-21	1051-1055	acid	abstract[58]|substance|abstract[62]	giv[58]|giv|giv[62]	coref	11-7
10-22	1056-1062	levels	abstract[58]|abstract[62]	giv[58]|giv[62]	_	_
10-23	1063-1069	caused	_	_	_	_
10-24	1070-1072	by	_	_	_	_
10-25	1073-1079	purine	animal|event[64]	giv|giv[64]	coref|coref	11-45[81_64]|11-45[81_64]
10-26	1080-1089	ingestion	event[64]	giv[64]	_	_
10-27	1090-1092	in	_	_	_	_
10-28	1093-1100	healthy	person[65]	new[65]	_	_
10-29	1101-1109	subjects	person[65]	new[65]	_	_
10-30	1110-1111	.	_	_	_	_

#Text=The effect of the combined amino acid administration was stronger than that of the same glycine dose alone , indicating that a small amount of tryptophan provides an additional benefit to glycine alone in reducing the elevation in the serum uric acid levels after the ingestion of dietary purines .
11-1	1112-1115	The	abstract[66]	new[66]	_	_
11-2	1116-1122	effect	abstract[66]	new[66]	_	_
11-3	1123-1125	of	abstract[66]	new[66]	_	_
11-4	1126-1129	the	abstract[66]|organization[69]	new[66]|giv[69]	coref	20-26[174_69]
11-5	1130-1138	combined	abstract[66]|organization[69]	new[66]|giv[69]	_	_
11-6	1139-1144	amino	abstract[66]|object|organization[69]	new[66]|new|giv[69]	coref	28-25
11-7	1145-1149	acid	abstract[66]|substance|organization[69]	new[66]|giv|giv[69]	coref	11-42
11-8	1150-1164	administration	abstract[66]|organization[69]	new[66]|giv[69]	_	_
11-9	1165-1168	was	_	_	_	_
11-10	1169-1177	stronger	_	_	_	_
11-11	1178-1182	than	_	_	_	_
11-12	1183-1187	that	_	_	_	_
11-13	1188-1190	of	_	_	_	_
11-14	1191-1194	the	quantity[71]	new[71]	_	_
11-15	1195-1199	same	quantity[71]	new[71]	_	_
11-16	1200-1207	glycine	substance|quantity[71]	giv|new[71]	coref	11-32[75_0]
11-17	1208-1212	dose	quantity[71]	new[71]	_	_
11-18	1213-1218	alone	quantity[71]	new[71]	_	_
11-19	1219-1220	,	_	_	_	_
11-20	1221-1231	indicating	_	_	_	_
11-21	1232-1236	that	_	_	_	_
11-22	1237-1238	a	quantity[72]	new[72]	_	_
11-23	1239-1244	small	quantity[72]	new[72]	_	_
11-24	1245-1251	amount	quantity[72]	new[72]	_	_
11-25	1252-1254	of	quantity[72]	new[72]	_	_
11-26	1255-1265	tryptophan	quantity[72]|substance	new[72]|giv	coref	13-11
11-27	1266-1274	provides	_	_	_	_
11-28	1275-1277	an	abstract[74]	new[74]	_	_
11-29	1278-1288	additional	abstract[74]	new[74]	_	_
11-30	1289-1296	benefit	abstract[74]	new[74]	_	_
11-31	1297-1299	to	abstract[74]	new[74]	_	_
11-32	1300-1307	glycine	abstract[74]|substance[75]	new[74]|giv[75]	coref	12-7[0_75]
11-33	1308-1313	alone	abstract[74]|substance[75]	new[74]|giv[75]	_	_
11-34	1314-1316	in	_	_	_	_
11-35	1317-1325	reducing	_	_	_	_
11-36	1326-1329	the	abstract[76]	giv[76]	coref	16-7[119_76]
11-37	1330-1339	elevation	abstract[76]	giv[76]	_	_
11-38	1340-1342	in	abstract[76]	giv[76]	_	_
11-39	1343-1346	the	abstract[76]|abstract[80]	giv[76]|giv[80]	coref	15-10[112_80]
11-40	1347-1352	serum	abstract[76]|abstract|abstract[80]	giv[76]|giv|giv[80]	coref	28-3
11-41	1353-1357	uric	abstract[76]|abstract|abstract[80]	giv[76]|giv|giv[80]	coref	12-10
11-42	1358-1362	acid	abstract[76]|substance|abstract[80]	giv[76]|giv|giv[80]	coref	12-11
11-43	1363-1369	levels	abstract[76]|abstract[80]	giv[76]|giv[80]	_	_
11-44	1370-1375	after	abstract[76]|abstract[80]	giv[76]|giv[80]	_	_
11-45	1376-1379	the	abstract[76]|abstract[80]|event[81]	giv[76]|giv[80]|giv[81]	_	_
11-46	1380-1389	ingestion	abstract[76]|abstract[80]|event[81]	giv[76]|giv[80]|giv[81]	_	_
11-47	1390-1392	of	abstract[76]|abstract[80]|event[81]	giv[76]|giv[80]|giv[81]	_	_
11-48	1393-1400	dietary	abstract[76]|abstract[80]|event[81]|abstract|substance[83]	giv[76]|giv[80]|giv[81]|giv|new[83]	_	_
11-49	1401-1408	purines	abstract[76]|abstract[80]|event[81]|substance[83]	giv[76]|giv[80]|giv[81]|new[83]	_	_
11-50	1409-1410	.	_	_	_	_

#Text=In agreement with previous reports , glycine increased urinary uric acid excretion and enhanced urate clearance in the current study .
12-1	1411-1413	In	_	_	_	_
12-2	1414-1423	agreement	abstract[84]	new[84]	_	_
12-3	1424-1428	with	abstract[84]	new[84]	_	_
12-4	1429-1437	previous	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-5	1438-1445	reports	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-6	1446-1447	,	_	_	_	_
12-7	1448-1455	glycine	substance	giv	coref	13-9
12-8	1456-1465	increased	event	new	none	15-7
12-9	1466-1473	urinary	person|abstract[90]|abstract[91]	giv|giv[90]|new[91]	coref|coref|coref|coref|coref|coref|coref|coref|coref	13-17|15-13[115_90]|16-28[135_91]|13-17|15-13[115_90]|16-28[135_91]|13-17|15-13[115_90]|16-28[135_91]
12-10	1474-1478	uric	abstract|abstract[90]|abstract[91]	giv|giv[90]|new[91]	coref	15-5
12-11	1479-1483	acid	substance|abstract[90]|abstract[91]	giv|giv[90]|new[91]	coref	15-5[110_0]
12-12	1484-1493	excretion	abstract[90]|abstract[91]	giv[90]|new[91]	_	_
12-13	1494-1497	and	abstract[91]	new[91]	_	_
12-14	1498-1506	enhanced	abstract[91]|abstract[93]	new[91]|new[93]	coref	16-33[137_93]
12-15	1507-1512	urate	abstract[91]|abstract|abstract[93]	new[91]|new|new[93]	coref	16-33
12-16	1513-1522	clearance	abstract[91]|abstract[93]	new[91]|new[93]	_	_
12-17	1523-1525	in	_	_	_	_
12-18	1526-1529	the	event[94]	giv[94]	coref	25-2[204_94]
12-19	1530-1537	current	event[94]	giv[94]	_	_
12-20	1538-1543	study	event[94]	giv[94]	_	_
12-21	1544-1545	.	_	_	_	_

#Text=The authors previously reported that continual supplementation with glycine and tryptophan led to an increase in urinary pH .
13-1	1546-1549	The	person[95]	new[95]	_	_
13-2	1550-1557	authors	person[95]	new[95]	_	_
13-3	1558-1568	previously	_	_	_	_
13-4	1569-1577	reported	_	_	_	_
13-5	1578-1582	that	_	_	_	_
13-6	1583-1592	continual	abstract[96]	giv[96]	coref	16-16[125_96]
13-7	1593-1608	supplementation	abstract[96]	giv[96]	_	_
13-8	1609-1613	with	abstract[96]	giv[96]	_	_
13-9	1614-1621	glycine	abstract[96]|substance|substance[98]	giv[96]|giv|giv[98]	coref|coref|coref|coref	14-1|16-14[123_98]|14-1|16-14[123_98]
13-10	1622-1625	and	abstract[96]|substance[98]	giv[96]|giv[98]	_	_
13-11	1626-1636	tryptophan	abstract[96]|substance[98]|substance	giv[96]|giv[98]|giv	coref	16-16
13-12	1637-1640	led	_	_	_	_
13-13	1641-1643	to	_	_	_	_
13-14	1644-1646	an	abstract[100]	new[100]	_	_
13-15	1647-1655	increase	abstract[100]	new[100]	_	_
13-16	1656-1658	in	abstract[100]	new[100]	_	_
13-17	1659-1666	urinary	abstract[100]|person|abstract[102]	new[100]|giv|new[102]	coref|coref|coref|coref	15-10[0_102]|16-10|15-10[0_102]|16-10
13-18	1667-1669	pH	abstract[100]|abstract[102]	new[100]|new[102]	_	_
13-19	1670-1671	.	_	_	_	_

#Text=Glycine exhibits a buffering action and it is often used as an antacid .
14-1	1672-1679	Glycine	substance	giv	coref	16-14
14-2	1680-1688	exhibits	_	_	_	_
14-3	1689-1690	a	abstract[105]	new[105]	ana	14-7[0_105]
14-4	1691-1700	buffering	abstract|abstract[105]	new|new[105]	_	_
14-5	1701-1707	action	abstract[105]	new[105]	_	_
14-6	1708-1711	and	_	_	_	_
14-7	1712-1714	it	abstract	giv	coref	23-6[196_0]
14-8	1715-1717	is	_	_	_	_
14-9	1718-1723	often	_	_	_	_
14-10	1724-1728	used	_	_	_	_
14-11	1729-1731	as	_	_	_	_
14-12	1732-1734	an	_	_	_	_
14-13	1735-1742	antacid	_	_	_	_
14-14	1743-1744	.	_	_	_	_

#Text=The water solubility of uric acid increases with increasing pH levels and uric acid excretion is more favorable in alkaline urine than in acidic urine .
15-1	1745-1748	The	abstract[108]	new[108]	_	_
15-2	1749-1754	water	substance|abstract[108]	new|new[108]	_	_
15-3	1755-1765	solubility	abstract[108]	new[108]	_	_
15-4	1766-1768	of	abstract[108]	new[108]	_	_
15-5	1769-1773	uric	abstract[108]|abstract|substance[110]	new[108]|giv|giv[110]	coref|coref|coref|coref	15-13|15-14[0_110]|15-13|15-14[0_110]
15-6	1774-1778	acid	abstract[108]|substance[110]	new[108]|giv[110]	_	_
15-7	1779-1788	increases	event	new	coref	30-1[248_0]
15-8	1789-1793	with	_	_	_	_
15-9	1794-1804	increasing	_	_	_	_
15-10	1805-1807	pH	abstract|abstract[112]	giv|giv[112]	coref|coref|coref|coref	16-10[121_0]|28-1[235_112]|16-10[121_0]|28-1[235_112]
15-11	1808-1814	levels	abstract[112]	giv[112]	_	_
15-12	1815-1818	and	abstract[112]	giv[112]	_	_
15-13	1819-1823	uric	abstract[112]|abstract|abstract[115]	giv[112]|giv|giv[115]	coref|coref|coref|coref	16-23|16-28[134_115]|16-23|16-28[134_115]
15-14	1824-1828	acid	abstract[112]|substance|abstract[115]	giv[112]|giv|giv[115]	coref	16-22[130_0]
15-15	1829-1838	excretion	abstract[112]|abstract[115]	giv[112]|giv[115]	_	_
15-16	1839-1841	is	_	_	_	_
15-17	1842-1846	more	_	_	_	_
15-18	1847-1856	favorable	_	_	_	_
15-19	1857-1859	in	_	_	_	_
15-20	1860-1868	alkaline	substance[116]	new[116]	_	_
15-21	1869-1874	urine	substance[116]	new[116]	_	_
15-22	1875-1879	than	_	_	_	_
15-23	1880-1882	in	_	_	_	_
15-24	1883-1889	acidic	substance[117]	new[117]	_	_
15-25	1890-1895	urine	substance[117]	new[117]	_	_
15-26	1896-1897	.	_	_	_	_

#Text=Therefore , it is possible that the elevation in urinary pH caused by glycine and tryptophan supplementation enhanced the solubility of urinary uric acid , thereby elevating urinary uric acid excretion and urate clearance .
16-1	1898-1907	Therefore	_	_	_	_
16-2	1908-1909	,	_	_	_	_
16-3	1910-1912	it	abstract	new	cata	16-3[0_126]
16-4	1913-1915	is	_	_	_	_
16-5	1916-1924	possible	_	_	_	_
16-6	1925-1929	that	abstract[126]	new[126]	_	_
16-7	1930-1933	the	abstract[119]|abstract[126]	giv[119]|new[126]	coref	20-4[166_119]
16-8	1934-1943	elevation	abstract[119]|abstract[126]	giv[119]|new[126]	_	_
16-9	1944-1946	in	abstract[119]|abstract[126]	giv[119]|new[126]	_	_
16-10	1947-1954	urinary	abstract[119]|person|abstract[121]|abstract[126]	giv[119]|giv|giv[121]|new[126]	coref|coref|coref|coref	16-22|18-4[149_121]|16-22|18-4[149_121]
16-11	1955-1957	pH	abstract[119]|abstract[121]|abstract[126]	giv[119]|giv[121]|new[126]	_	_
16-12	1958-1964	caused	abstract[126]	new[126]	_	_
16-13	1965-1967	by	abstract[126]	new[126]	_	_
16-14	1968-1975	glycine	substance|substance[123]|abstract[126]	giv|giv[123]|new[126]	coref|coref	20-14|20-14
16-15	1976-1979	and	substance[123]|abstract[126]	giv[123]|new[126]	_	_
16-16	1980-1990	tryptophan	substance[123]|substance|abstract[125]|abstract[126]	giv[123]|giv|giv[125]|new[126]	coref|coref|coref|coref	25-6[205_125]|25-9|25-6[205_125]|25-9
16-17	1991-2006	supplementation	substance[123]|abstract[125]|abstract[126]	giv[123]|giv[125]|new[126]	_	_
16-18	2007-2015	enhanced	abstract[126]	new[126]	_	_
16-19	2016-2019	the	abstract[126]|abstract[127]	new[126]|new[127]	_	_
16-20	2020-2030	solubility	abstract[126]|abstract[127]	new[126]|new[127]	_	_
16-21	2031-2033	of	abstract[126]|abstract[127]	new[126]|new[127]	_	_
16-22	2034-2041	urinary	abstract[126]|abstract[127]|person|substance[130]	new[126]|new[127]|giv|giv[130]	coref|coref|coref|coref	16-28|16-30[0_130]|16-28|16-30[0_130]
16-23	2042-2046	uric	abstract[126]|abstract[127]|abstract|substance[130]	new[126]|new[127]|giv|giv[130]	coref	16-29
16-24	2047-2051	acid	abstract[126]|abstract[127]|substance[130]	new[126]|new[127]|giv[130]	_	_
16-25	2052-2053	,	_	_	_	_
16-26	2054-2061	thereby	_	_	_	_
16-27	2062-2071	elevating	_	_	_	_
16-28	2072-2079	urinary	person|abstract[134]|abstract[135]	giv|giv[134]|giv[135]	coref|coref|coref|coref|coref|coref|coref|coref|coref	18-6|20-29[177_134]|30-4[252_135]|18-6|20-29[177_134]|30-4[252_135]|18-6|20-29[177_134]|30-4[252_135]
16-29	2080-2084	uric	abstract|abstract[134]|abstract[135]	giv|giv[134]|giv[135]	coref	18-11
16-30	2085-2089	acid	substance|abstract[134]|abstract[135]	giv|giv[134]|giv[135]	coref	18-12
16-31	2090-2099	excretion	abstract[134]|abstract[135]	giv[134]|giv[135]	_	_
16-32	2100-2103	and	abstract[135]	giv[135]	_	_
16-33	2104-2109	urate	abstract[135]|abstract|abstract[137]	giv[135]|giv|giv[137]	coref|coref|coref|coref	20-33|20-33[179_137]|20-33|20-33[179_137]
16-34	2110-2119	clearance	abstract[135]|abstract[137]	giv[135]|giv[137]	_	_
16-35	2120-2121	.	_	_	_	_

#Text=Previous studies provide physiological , physicochemical and clinical validation for the use of citrate salt in the treatment of some types of lithiasis .
17-1	2122-2130	Previous	abstract[138]	new[138]	coref	24-1[200_138]
17-2	2131-2138	studies	abstract[138]	new[138]	_	_
17-3	2139-2146	provide	_	_	_	_
17-4	2147-2160	physiological	abstract[139]	new[139]	_	_
17-5	2161-2162	,	abstract[139]	new[139]	_	_
17-6	2163-2178	physicochemical	abstract[139]	new[139]	_	_
17-7	2179-2182	and	abstract[139]	new[139]	_	_
17-8	2183-2191	clinical	abstract[139]	new[139]	_	_
17-9	2192-2202	validation	abstract[139]	new[139]	_	_
17-10	2203-2206	for	abstract[139]	new[139]	_	_
17-11	2207-2210	the	abstract[139]|abstract[140]	new[139]|new[140]	_	_
17-12	2211-2214	use	abstract[139]|abstract[140]	new[139]|new[140]	_	_
17-13	2215-2217	of	abstract[139]|abstract[140]	new[139]|new[140]	_	_
17-14	2218-2225	citrate	abstract[139]|abstract[140]|person|substance[142]	new[139]|new[140]|new|new[142]	coref|coref	18-1|18-1
17-15	2226-2230	salt	abstract[139]|abstract[140]|substance[142]	new[139]|new[140]|new[142]	_	_
17-16	2231-2233	in	abstract[139]|abstract[140]|substance[142]	new[139]|new[140]|new[142]	_	_
17-17	2234-2237	the	abstract[139]|abstract[140]|substance[142]|abstract[143]	new[139]|new[140]|new[142]|new[143]	_	_
17-18	2238-2247	treatment	abstract[139]|abstract[140]|substance[142]|abstract[143]	new[139]|new[140]|new[142]|new[143]	_	_
17-19	2248-2250	of	abstract[139]|abstract[140]|substance[142]|abstract[143]	new[139]|new[140]|new[142]|new[143]	_	_
17-20	2251-2255	some	abstract[139]|abstract[140]|substance[142]|abstract[143]|abstract[144]	new[139]|new[140]|new[142]|new[143]|new[144]	_	_
17-21	2256-2261	types	abstract[139]|abstract[140]|substance[142]|abstract[143]|abstract[144]	new[139]|new[140]|new[142]|new[143]|new[144]	_	_
17-22	2262-2264	of	abstract[139]|abstract[140]|substance[142]|abstract[143]|abstract[144]	new[139]|new[140]|new[142]|new[143]|new[144]	_	_
17-23	2265-2274	lithiasis	abstract[139]|abstract[140]|substance[142]|abstract[143]|abstract[144]|abstract	new[139]|new[140]|new[142]|new[143]|new[144]|new	coref	18-11[153_0]
17-24	2275-2276	.	_	_	_	_

#Text=Citrate salts treatment substantially increased urinary pH in patients with uric acid lithiasis , however , there was no significant change in the amount of urinary uric acid .
18-1	2277-2284	Citrate	substance|substance[147]	giv|new[147]	coref|coref|coref|coref	19-10|19-10[162_147]|19-10|19-10[162_147]
18-2	2285-2290	salts	substance[147]	new[147]	_	_
18-3	2291-2300	treatment	_	_	_	_
18-4	2301-2314	substantially	abstract[149]	giv[149]	coref	20-7[168_149]
18-5	2315-2324	increased	abstract[149]	giv[149]	_	_
18-6	2325-2332	urinary	person|abstract[149]	giv|giv[149]	coref	18-26
18-7	2333-2335	pH	abstract[149]	giv[149]	_	_
18-8	2336-2338	in	abstract[149]	giv[149]	_	_
18-9	2339-2347	patients	abstract[149]|person[150]	giv[149]|new[150]	_	_
18-10	2348-2352	with	abstract[149]|person[150]	giv[149]|new[150]	_	_
18-11	2353-2357	uric	abstract[149]|person[150]|abstract|abstract[153]	giv[149]|new[150]|giv|giv[153]	coref|coref	18-27|18-27
18-12	2358-2362	acid	abstract[149]|person[150]|substance|abstract[153]	giv[149]|new[150]|giv|giv[153]	coref	18-26[158_0]
18-13	2363-2372	lithiasis	abstract[149]|person[150]|abstract[153]	giv[149]|new[150]|giv[153]	_	_
18-14	2373-2374	,	_	_	_	_
18-15	2375-2382	however	_	_	_	_
18-16	2383-2384	,	_	_	_	_
18-17	2385-2390	there	_	_	_	_
18-18	2391-2394	was	_	_	_	_
18-19	2395-2397	no	abstract[154]	new[154]	_	_
18-20	2398-2409	significant	abstract[154]	new[154]	_	_
18-21	2410-2416	change	abstract[154]	new[154]	_	_
18-22	2417-2419	in	abstract[154]	new[154]	_	_
18-23	2420-2423	the	abstract[154]|quantity[155]	new[154]|new[155]	_	_
18-24	2424-2430	amount	abstract[154]|quantity[155]	new[154]|new[155]	_	_
18-25	2431-2433	of	abstract[154]|quantity[155]	new[154]|new[155]	_	_
18-26	2434-2441	urinary	abstract[154]|quantity[155]|person|substance[158]	new[154]|new[155]|giv|giv[158]	coref|coref|coref|coref	20-7|20-30[0_158]|20-7|20-30[0_158]
18-27	2442-2446	uric	abstract[154]|quantity[155]|abstract|substance[158]	new[154]|new[155]|giv|giv[158]	coref	20-29
18-28	2447-2451	acid	abstract[154]|quantity[155]|substance[158]	new[154]|new[155]|giv[158]	_	_
18-29	2452-2453	.	_	_	_	_

#Text=The mixture of amino acids might be superior to citrate salts in the prevention or treatment of hyperuricemia .
19-1	2454-2457	The	substance[159]	new[159]	_	_
19-2	2458-2465	mixture	substance[159]	new[159]	_	_
19-3	2466-2468	of	substance[159]	new[159]	_	_
19-4	2469-2474	amino	substance[159]|substance[160]	new[159]|new[160]	coref	28-24[243_160]
19-5	2475-2480	acids	substance[159]|substance[160]	new[159]|new[160]	_	_
19-6	2481-2486	might	_	_	_	_
19-7	2487-2489	be	_	_	_	_
19-8	2490-2498	superior	_	_	_	_
19-9	2499-2501	to	_	_	_	_
19-10	2502-2509	citrate	person|substance[162]	giv|giv[162]	_	_
19-11	2510-2515	salts	substance[162]	giv[162]	_	_
19-12	2516-2518	in	substance[162]	giv[162]	_	_
19-13	2519-2522	the	substance[162]|abstract[163]	giv[162]|new[163]	_	_
19-14	2523-2533	prevention	substance[162]|abstract[163]	giv[162]|new[163]	_	_
19-15	2534-2536	or	substance[162]	giv[162]	_	_
19-16	2537-2546	treatment	substance[162]|abstract[164]	giv[162]|new[164]	_	_
19-17	2547-2549	of	substance[162]|abstract[164]	giv[162]|new[164]	_	_
19-18	2550-2563	hyperuricemia	substance[162]|abstract[164]|abstract	giv[162]|new[164]|new	_	_
19-19	2564-2565	.	_	_	_	_

#Text=Herein , although the elevation of urinary pH induced by the ingestion of glycine alone was not significant compared with the effects of placebo , glycine administration enhanced uric acid excretion and urate clearance , raising the possibility of other mechanisms .
20-1	2566-2572	Herein	_	_	_	_
20-2	2573-2574	,	_	_	_	_
20-3	2575-2583	although	_	_	_	_
20-4	2584-2587	the	abstract[166]	giv[166]	coref	26-21[223_166]
20-5	2588-2597	elevation	abstract[166]	giv[166]	_	_
20-6	2598-2600	of	abstract[166]	giv[166]	_	_
20-7	2601-2608	urinary	abstract[166]|person|abstract[168]	giv[166]|giv|giv[168]	coref|coref|coref|coref	25-15|25-15[209_168]|25-15|25-15[209_168]
20-8	2609-2611	pH	abstract[166]|abstract[168]	giv[166]|giv[168]	_	_
20-9	2612-2619	induced	_	_	_	_
20-10	2620-2622	by	_	_	_	_
20-11	2623-2626	the	substance[169]	new[169]	coref	28-15[0_169]
20-12	2627-2636	ingestion	substance[169]	new[169]	_	_
20-13	2637-2639	of	substance[169]	new[169]	_	_
20-14	2640-2647	glycine	substance[169]|substance	new[169]|giv	coref	20-26
20-15	2648-2653	alone	_	_	_	_
20-16	2654-2657	was	_	_	_	_
20-17	2658-2661	not	_	_	_	_
20-18	2662-2673	significant	_	_	_	_
20-19	2674-2682	compared	_	_	_	_
20-20	2683-2687	with	_	_	_	_
20-21	2688-2691	the	abstract[171]	giv[171]	_	_
20-22	2692-2699	effects	abstract[171]	giv[171]	_	_
20-23	2700-2702	of	abstract[171]	giv[171]	_	_
20-24	2703-2710	placebo	abstract[171]|abstract	giv[171]|new	_	_
20-25	2711-2712	,	abstract[171]	giv[171]	_	_
20-26	2713-2720	glycine	abstract[171]|substance|organization[174]	giv[171]|giv|giv[174]	coref|coref	23-3|23-3
20-27	2721-2735	administration	abstract[171]|organization[174]	giv[171]|giv[174]	_	_
20-28	2736-2744	enhanced	abstract[171]	giv[171]	_	_
20-29	2745-2749	uric	abstract[171]|abstract|abstract[177]	giv[171]|giv|giv[177]	coref|coref|coref|coref	23-10|25-20[213_177]|23-10|25-20[213_177]
20-30	2750-2754	acid	abstract[171]|substance|abstract[177]	giv[171]|giv|giv[177]	coref	23-10[198_0]
20-31	2755-2764	excretion	abstract[171]|abstract[177]	giv[171]|giv[177]	_	_
20-32	2765-2768	and	abstract[171]	giv[171]	_	_
20-33	2769-2774	urate	abstract[171]|abstract|abstract[179]	giv[171]|giv|giv[179]	coref|coref|coref|coref	21-1|25-23[215_179]|21-1|25-23[215_179]
20-34	2775-2784	clearance	abstract[171]|abstract[179]	giv[171]|giv[179]	_	_
20-35	2785-2786	,	_	_	_	_
20-36	2787-2794	raising	_	_	_	_
20-37	2795-2798	the	abstract[180]	new[180]	_	_
20-38	2799-2810	possibility	abstract[180]	new[180]	_	_
20-39	2811-2813	of	abstract[180]	new[180]	_	_
20-40	2814-2819	other	abstract[180]|abstract[181]	new[180]|new[181]	_	_
20-41	2820-2830	mechanisms	abstract[180]|abstract[181]	new[180]|new[181]	_	_
20-42	2831-2832	.	_	_	_	_

#Text=Urate transporter 1 ( URAT1 ) , a primary reabsorptive urate transporter that is targeted by pyrazinamide , reportedly disables glycine-induced uricosuria .
21-1	2833-2838	Urate	animal|abstract[183]	giv|new[183]	appos|coref|appos|coref	21-5[0_183]|21-11|21-5[0_183]|21-11
21-2	2839-2850	transporter	abstract[183]	new[183]	_	_
21-3	2851-2852	1	abstract[183]	new[183]	_	_
21-4	2853-2854	(	_	_	_	_
21-5	2855-2860	URAT1	abstract	giv	coref	21-8[186_0]
21-6	2861-2862	)	_	_	_	_
21-7	2863-2864	,	_	_	_	_
21-8	2865-2866	a	abstract[186]	giv[186]	coref	23-17[0_186]
21-9	2867-2874	primary	abstract[186]	giv[186]	_	_
21-10	2875-2887	reabsorptive	abstract[186]	giv[186]	_	_
21-11	2888-2893	urate	animal|abstract[186]	giv|giv[186]	coref	22-6
21-12	2894-2905	transporter	abstract[186]	giv[186]	_	_
21-13	2906-2910	that	_	_	_	_
21-14	2911-2913	is	_	_	_	_
21-15	2914-2922	targeted	_	_	_	_
21-16	2923-2925	by	_	_	_	_
21-17	2926-2938	pyrazinamide	object	new	coref	22-1
21-18	2939-2940	,	_	_	_	_
21-19	2941-2951	reportedly	_	_	_	_
21-20	2952-2960	disables	_	_	_	_
21-21	2961-2976	glycine-induced	substance[188]	new[188]	_	_
21-22	2977-2987	uricosuria	substance[188]	new[188]	_	_
21-23	2988-2989	.	_	_	_	_

#Text=Pyrazinamide may reflect the enhanced urate reabsorption following the exchange of its active metabolite .
22-1	2990-3002	Pyrazinamide	substance	giv	ana	22-12
22-2	3003-3006	may	_	_	_	_
22-3	3007-3014	reflect	_	_	_	_
22-4	3015-3018	the	abstract[191]	new[191]	_	_
22-5	3019-3027	enhanced	abstract[191]	new[191]	_	_
22-6	3028-3033	urate	substance|abstract[191]	giv|new[191]	coref	25-23
22-7	3034-3046	reabsorption	abstract[191]	new[191]	_	_
22-8	3047-3056	following	_	_	_	_
22-9	3057-3060	the	event[192]	new[192]	_	_
22-10	3061-3069	exchange	event[192]	new[192]	_	_
22-11	3070-3072	of	event[192]	new[192]	_	_
22-12	3073-3076	its	event[192]|substance|substance[194]	new[192]|giv|new[194]	_	_
22-13	3077-3083	active	event[192]|substance[194]	new[192]|new[194]	_	_
22-14	3084-3094	metabolite	event[192]|substance[194]	new[192]|new[194]	_	_
22-15	3095-3096	.	_	_	_	_

#Text=Thus , glycine may inhibit the reabsorptive action of uric acid , which is induced by URAT1 .
23-1	3097-3101	Thus	_	_	_	_
23-2	3102-3103	,	_	_	_	_
23-3	3104-3111	glycine	substance	giv	coref	24-10[202_0]
23-4	3112-3115	may	_	_	_	_
23-5	3116-3123	inhibit	_	_	_	_
23-6	3124-3127	the	abstract[196]	giv[196]	_	_
23-7	3128-3140	reabsorptive	abstract[196]	giv[196]	_	_
23-8	3141-3147	action	abstract[196]	giv[196]	_	_
23-9	3148-3150	of	abstract[196]	giv[196]	_	_
23-10	3151-3155	uric	abstract[196]|abstract|substance[198]	giv[196]|giv|giv[198]	coref|coref|coref|coref	25-18[211_0]|25-20[0_198]|25-18[211_0]|25-20[0_198]
23-11	3156-3160	acid	abstract[196]|substance[198]	giv[196]|giv[198]	_	_
23-12	3161-3162	,	_	_	_	_
23-13	3163-3168	which	_	_	_	_
23-14	3169-3171	is	_	_	_	_
23-15	3172-3179	induced	_	_	_	_
23-16	3180-3182	by	_	_	_	_
23-17	3183-3188	URAT1	abstract	giv	coref	24-12
23-18	3189-3190	.	_	_	_	_

#Text=Further studies are needed to elucidate the action of glycine on URAT1 .
24-1	3191-3198	Further	abstract[200]	giv[200]	coref	33-1[284_200]
24-2	3199-3206	studies	abstract[200]	giv[200]	_	_
24-3	3207-3210	are	_	_	_	_
24-4	3211-3217	needed	_	_	_	_
24-5	3218-3220	to	_	_	_	_
24-6	3221-3230	elucidate	_	_	_	_
24-7	3231-3234	the	abstract[201]	new[201]	coref	26-17[220_201]
24-8	3235-3241	action	abstract[201]	new[201]	_	_
24-9	3242-3244	of	abstract[201]	new[201]	_	_
24-10	3245-3252	glycine	abstract[201]|substance[202]	new[201]|giv[202]	coref	26-31[0_202]
24-11	3253-3255	on	abstract[201]|substance[202]	new[201]|giv[202]	_	_
24-12	3256-3261	URAT1	abstract[201]|substance[202]|substance	new[201]|giv[202]|giv	coref	26-7
24-13	3262-3263	.	_	_	_	_

#Text=In the current study , the supplementation with tryptophan alone had no influence on urinary pH , urinary uric acid excretion or urate clearance .
25-1	3264-3266	In	_	_	_	_
25-2	3267-3270	the	event[204]	giv[204]	coref	34-5[294_204]
25-3	3271-3278	current	event[204]	giv[204]	_	_
25-4	3279-3284	study	event[204]	giv[204]	_	_
25-5	3285-3286	,	_	_	_	_
25-6	3287-3290	the	abstract[205]	giv[205]	ana	26-25[0_205]
25-7	3291-3306	supplementation	abstract[205]	giv[205]	_	_
25-8	3307-3311	with	abstract[205]	giv[205]	_	_
25-9	3312-3322	tryptophan	abstract[205]|substance	giv[205]|giv	coref	26-5[217_0]
25-10	3323-3328	alone	_	_	_	_
25-11	3329-3332	had	_	_	_	_
25-12	3333-3335	no	abstract[207]	new[207]	coref	26-25[225_207]
25-13	3336-3345	influence	abstract[207]	new[207]	_	_
25-14	3346-3348	on	abstract[207]	new[207]	_	_
25-15	3349-3356	urinary	abstract[207]|person|abstract[209]	new[207]|giv|giv[209]	coref|coref	25-18|25-18
25-16	3357-3359	pH	abstract[207]|abstract[209]	new[207]|giv[209]	_	_
25-17	3360-3361	,	abstract[207]	new[207]	_	_
25-18	3362-3369	urinary	abstract[207]|person|abstract[211]	new[207]|giv|giv[211]	coref|coref|coref|coref	26-21[0_211]|30-4|26-21[0_211]|30-4
25-19	3370-3374	uric	abstract[207]|abstract[211]	new[207]|giv[211]	_	_
25-20	3375-3379	acid	abstract[207]|substance|abstract[213]	new[207]|giv|giv[213]	coref|coref|coref|coref	26-22|30-4[251_213]|26-22|30-4[251_213]
25-21	3380-3389	excretion	abstract[207]|abstract[213]	new[207]|giv[213]	_	_
25-22	3390-3392	or	abstract[207]	new[207]	_	_
25-23	3393-3398	urate	abstract[207]|abstract|abstract[215]	new[207]|giv|giv[215]	coref|coref	30-8[254_215]|30-8[254_215]
25-24	3399-3408	clearance	abstract[207]|abstract[215]	new[207]|giv[215]	_	_
25-25	3409-3410	.	_	_	_	_

#Text=As the effect of tryptophan on URAT1 might be structurally difficult , tryptophan might have exerted an indirect action against uric acid elevation via its influence on the action of glycine .
26-1	3411-3413	As	_	_	_	_
26-2	3414-3417	the	abstract[216]	new[216]	_	_
26-3	3418-3424	effect	abstract[216]	new[216]	_	_
26-4	3425-3427	of	abstract[216]	new[216]	_	_
26-5	3428-3438	tryptophan	abstract[216]|substance[217]	new[216]|giv[217]	coref	26-13[0_217]
26-6	3439-3441	on	abstract[216]|substance[217]	new[216]|giv[217]	_	_
26-7	3442-3447	URAT1	abstract[216]|substance[217]|abstract	new[216]|giv[217]|giv	_	_
26-8	3448-3453	might	_	_	_	_
26-9	3454-3456	be	_	_	_	_
26-10	3457-3469	structurally	_	_	_	_
26-11	3470-3479	difficult	_	_	_	_
26-12	3480-3481	,	_	_	_	_
26-13	3482-3492	tryptophan	substance	giv	coref	27-3
26-14	3493-3498	might	_	_	_	_
26-15	3499-3503	have	_	_	_	_
26-16	3504-3511	exerted	_	_	_	_
26-17	3512-3514	an	abstract[220]	giv[220]	_	_
26-18	3515-3523	indirect	abstract[220]	giv[220]	_	_
26-19	3524-3530	action	abstract[220]	giv[220]	_	_
26-20	3531-3538	against	abstract[220]	giv[220]	_	_
26-21	3539-3543	uric	abstract[220]|abstract|abstract[223]	giv[220]|giv|giv[223]	coref|coref|coref|coref	27-12|12-8[0_223]|27-12|12-8[0_223]
26-22	3544-3548	acid	abstract[220]|substance|abstract[223]	giv[220]|giv|giv[223]	coref	27-13
26-23	3549-3558	elevation	abstract[220]|abstract[223]	giv[220]|giv[223]	_	_
26-24	3559-3562	via	abstract[220]|abstract[223]	giv[220]|giv[223]	_	_
26-25	3563-3566	its	abstract[220]|abstract[223]|abstract|abstract[225]	giv[220]|giv[223]|giv|giv[225]	coref|coref	31-12[262_0]|31-12[262_0]
26-26	3567-3576	influence	abstract[220]|abstract[223]|abstract[225]	giv[220]|giv[223]|giv[225]	_	_
26-27	3577-3579	on	abstract[220]|abstract[223]|abstract[225]	giv[220]|giv[223]|giv[225]	_	_
26-28	3580-3583	the	abstract[220]|abstract[223]|abstract[225]|abstract[226]	giv[220]|giv[223]|giv[225]|new[226]	_	_
26-29	3584-3590	action	abstract[220]|abstract[223]|abstract[225]|abstract[226]	giv[220]|giv[223]|giv[225]|new[226]	_	_
26-30	3591-3593	of	abstract[220]|abstract[223]|abstract[225]|abstract[226]	giv[220]|giv[223]|giv[225]|new[226]	_	_
26-31	3594-3601	glycine	abstract[220]|abstract[223]|abstract[225]|abstract[226]|substance	giv[220]|giv[223]|giv[225]|new[226]|giv	coref	27-10[230_0]
26-32	3602-3603	.	_	_	_	_

#Text=Specifically , tryptophan might promote the direct action of glycine against uric acid elevation .
27-1	3604-3616	Specifically	_	_	_	_
27-2	3617-3618	,	_	_	_	_
27-3	3619-3629	tryptophan	substance	giv	coref	28-8
27-4	3630-3635	might	_	_	_	_
27-5	3636-3643	promote	_	_	_	_
27-6	3644-3647	the	event[229]	new[229]	_	_
27-7	3648-3654	direct	event[229]	new[229]	_	_
27-8	3655-3661	action	event[229]	new[229]	_	_
27-9	3662-3664	of	event[229]	new[229]	_	_
27-10	3665-3672	glycine	event[229]|substance[230]	new[229]|giv[230]	coref	29-1[0_230]
27-11	3673-3680	against	event[229]|substance[230]	new[229]|giv[230]	_	_
27-12	3681-3685	uric	event[229]|substance[230]|abstract|abstract[233]	new[229]|giv[230]|giv|giv[233]	coref|coref	33-20|33-20
27-13	3686-3690	acid	event[229]|substance[230]|substance|abstract[233]	new[229]|giv[230]|giv|giv[233]	coref	33-21
27-14	3691-3700	elevation	event[229]|substance[230]|abstract[233]	new[229]|giv[230]|giv[233]	_	_
27-15	3701-3702	.	_	_	_	_

#Text=The maximum serum levels of glycine and tryptophan are achieved within an hour of ingestion , which is followed by rapid decreases as the amino acids are metabolized .
28-1	3703-3706	The	abstract[235]	giv[235]	coref	35-19[317_235]
28-2	3707-3714	maximum	abstract[235]	giv[235]	_	_
28-3	3715-3720	serum	substance|abstract[235]	giv|giv[235]	coref	32-8
28-4	3721-3727	levels	abstract[235]	giv[235]	_	_
28-5	3728-3730	of	abstract[235]	giv[235]	_	_
28-6	3731-3738	glycine	abstract[235]|substance|substance[237]	giv[235]|new|new[237]	coref|coref	31-16[264_237]|31-16[264_237]
28-7	3739-3742	and	abstract[235]|substance[237]	giv[235]|new[237]	_	_
28-8	3743-3753	tryptophan	abstract[235]|substance[237]|substance	giv[235]|new[237]|giv	coref	31-18
28-9	3754-3757	are	_	_	_	_
28-10	3758-3766	achieved	_	_	_	_
28-11	3767-3773	within	_	_	_	_
28-12	3774-3776	an	time[239]	new[239]	_	_
28-13	3777-3781	hour	time[239]	new[239]	_	_
28-14	3782-3784	of	time[239]	new[239]	_	_
28-15	3785-3794	ingestion	time[239]|event	new[239]|giv	_	_
28-16	3795-3796	,	_	_	_	_
28-17	3797-3802	which	_	_	_	_
28-18	3803-3805	is	_	_	_	_
28-19	3806-3814	followed	_	_	_	_
28-20	3815-3817	by	_	_	_	_
28-21	3818-3823	rapid	abstract[241]	new[241]	_	_
28-22	3824-3833	decreases	abstract[241]	new[241]	_	_
28-23	3834-3836	as	_	_	_	_
28-24	3837-3840	the	substance[243]	giv[243]	coref	29-17[247_243]
28-25	3841-3846	amino	object|substance[243]	giv|giv[243]	_	_
28-26	3847-3852	acids	substance[243]	giv[243]	_	_
28-27	3853-3856	are	_	_	_	_
28-28	3857-3868	metabolized	_	_	_	_
28-29	3869-3870	.	_	_	_	_

#Text=Glycine metabolizes various end-products , namely glutathione , nucleic acid bases , heme , creatine and bile acids .
29-1	3871-3878	Glycine	substance	giv	coref	30-12
29-2	3879-3890	metabolizes	_	_	_	_
29-3	3891-3898	various	substance[245]	new[245]	appos	29-6[246_245]
29-4	3899-3911	end-products	substance[245]	new[245]	_	_
29-5	3912-3913	,	_	_	_	_
29-6	3914-3920	namely	substance[246]	giv[246]	coref	30-27[0_246]
29-7	3921-3932	glutathione	substance[246]	giv[246]	_	_
29-8	3933-3934	,	substance[246]	giv[246]	_	_
29-9	3935-3942	nucleic	substance[246]	giv[246]	_	_
29-10	3943-3947	acid	substance[246]	giv[246]	_	_
29-11	3948-3953	bases	substance[246]	giv[246]	_	_
29-12	3954-3955	,	substance[246]	giv[246]	_	_
29-13	3956-3960	heme	substance[246]	giv[246]	_	_
29-14	3961-3962	,	substance[246]	giv[246]	_	_
29-15	3963-3971	creatine	substance[246]	giv[246]	_	_
29-16	3972-3975	and	_	_	_	_
29-17	3976-3980	bile	substance[247]	giv[247]	_	_
29-18	3981-3986	acids	substance[247]	giv[247]	_	_
29-19	3987-3988	.	_	_	_	_

#Text=The increases in urinary creatinine excretion and creatinine clearance following the glycine challenge suggest that glycine might be partially absorbed back and metabolized to creatinine through creatine .
30-1	3989-3992	The	event[248]	new[248]	coref	32-4[271_248]
30-2	3993-4002	increases	event[248]	new[248]	_	_
30-3	4003-4005	in	event[248]	new[248]	_	_
30-4	4006-4013	urinary	event[248]|person|abstract[251]|abstract[252]	new[248]|giv|giv[251]|giv[252]	coref|coref|coref|coref|coref|coref	32-12|32-12[277_251]|32-12|32-12[277_251]|32-12|32-12[277_251]
30-5	4014-4024	creatinine	event[248]|substance|abstract[251]|abstract[252]	new[248]|new|giv[251]|giv[252]	coref	30-8
30-6	4025-4034	excretion	event[248]|abstract[251]|abstract[252]	new[248]|giv[251]|giv[252]	_	_
30-7	4035-4038	and	event[248]|abstract[252]	new[248]|giv[252]	_	_
30-8	4039-4049	creatinine	event[248]|abstract[252]|substance|abstract[254]	new[248]|giv[252]|giv|giv[254]	coref|coref	30-25[258_0]|30-25[258_0]
30-9	4050-4059	clearance	event[248]|abstract[252]|abstract[254]	new[248]|giv[252]|giv[254]	_	_
30-10	4060-4069	following	_	_	_	_
30-11	4070-4073	the	event[256]	new[256]	_	_
30-12	4074-4081	glycine	substance|event[256]	giv|new[256]	coref	30-16
30-13	4082-4091	challenge	event[256]	new[256]	_	_
30-14	4092-4099	suggest	_	_	_	_
30-15	4100-4104	that	_	_	_	_
30-16	4105-4112	glycine	substance	giv	coref	31-16
30-17	4113-4118	might	_	_	_	_
30-18	4119-4121	be	_	_	_	_
30-19	4122-4131	partially	_	_	_	_
30-20	4132-4140	absorbed	_	_	_	_
30-21	4141-4145	back	_	_	_	_
30-22	4146-4149	and	_	_	_	_
30-23	4150-4161	metabolized	_	_	_	_
30-24	4162-4164	to	_	_	_	_
30-25	4165-4175	creatinine	substance[258]	giv[258]	coref	31-29[269_258]
30-26	4176-4183	through	substance[258]	giv[258]	_	_
30-27	4184-4192	creatine	substance[258]|substance	giv[258]|giv	_	_
30-28	4193-4194	.	_	_	_	_

#Text=Conversely , these urinary parameters did not change in response to the simultaneous supplementation with glycine and tryptophan , suggesting the suppression of the conversion of glycine to creatinine by tryptophan .
31-1	4195-4205	Conversely	_	_	_	_
31-2	4206-4207	,	_	_	_	_
31-3	4208-4213	these	abstract[260]	new[260]	_	_
31-4	4214-4221	urinary	abstract[260]	new[260]	_	_
31-5	4222-4232	parameters	abstract[260]	new[260]	_	_
31-6	4233-4236	did	_	_	_	_
31-7	4237-4240	not	_	_	_	_
31-8	4241-4247	change	_	_	_	_
31-9	4248-4250	in	_	_	_	_
31-10	4251-4259	response	abstract[261]	new[261]	coref	32-19[0_261]
31-11	4260-4262	to	abstract[261]	new[261]	_	_
31-12	4263-4266	the	abstract[261]|abstract[262]	new[261]|giv[262]	coref	32-21[279_262]
31-13	4267-4279	simultaneous	abstract[261]|abstract[262]	new[261]|giv[262]	_	_
31-14	4280-4295	supplementation	abstract[261]|abstract[262]	new[261]|giv[262]	_	_
31-15	4296-4300	with	abstract[261]|abstract[262]	new[261]|giv[262]	_	_
31-16	4301-4308	glycine	abstract[261]|abstract[262]|substance|substance[264]	new[261]|giv[262]|giv|giv[264]	coref|coref|coref|coref	31-27|15-7[0_264]|31-27|15-7[0_264]
31-17	4309-4312	and	abstract[261]|abstract[262]|substance[264]	new[261]|giv[262]|giv[264]	_	_
31-18	4313-4323	tryptophan	abstract[261]|abstract[262]|substance[264]|substance	new[261]|giv[262]|giv[264]|giv	coref	31-31
31-19	4324-4325	,	_	_	_	_
31-20	4326-4336	suggesting	_	_	_	_
31-21	4337-4340	the	event[266]	new[266]	_	_
31-22	4341-4352	suppression	event[266]	new[266]	_	_
31-23	4353-4355	of	event[266]	new[266]	_	_
31-24	4356-4359	the	event[266]|event[267]	new[266]|new[267]	_	_
31-25	4360-4370	conversion	event[266]|event[267]	new[266]|new[267]	_	_
31-26	4371-4373	of	event[266]|event[267]	new[266]|new[267]	_	_
31-27	4374-4381	glycine	event[266]|event[267]|substance	new[266]|new[267]|giv	coref	32-13
31-28	4382-4384	to	event[266]|event[267]	new[266]|new[267]	_	_
31-29	4385-4395	creatinine	event[266]|event[267]|substance[269]	new[266]|new[267]|giv[269]	_	_
31-30	4396-4398	by	event[266]|event[267]|substance[269]	new[266]|new[267]|giv[269]	_	_
31-31	4399-4409	tryptophan	event[266]|event[267]|substance[269]|substance	new[266]|new[267]|giv[269]|giv	coref	32-25[282_0]
31-32	4410-4411	.	_	_	_	_

#Text=In fact , the increases in the serum glycine/creatinine ratio and urinary glycine excretion were more pronounced in response to supplementation with glycine and tryptophan than with glycine alone .
32-1	4412-4414	In	_	_	_	_
32-2	4415-4419	fact	_	_	_	_
32-3	4420-4421	,	_	_	_	_
32-4	4422-4425	the	event[271]	giv[271]	_	_
32-5	4426-4435	increases	event[271]	giv[271]	_	_
32-6	4436-4438	in	event[271]	giv[271]	_	_
32-7	4439-4442	the	event[271]|quantity[274]	giv[271]|new[274]	_	_
32-8	4443-4448	serum	event[271]|substance|quantity[274]	giv[271]|giv|new[274]	coref	35-19
32-9	4449-4467	glycine/creatinine	event[271]|substance|quantity[274]	giv[271]|new|new[274]	_	_
32-10	4468-4473	ratio	event[271]|quantity[274]	giv[271]|new[274]	_	_
32-11	4474-4477	and	event[271]	giv[271]	_	_
32-12	4478-4485	urinary	event[271]|person|abstract[277]	giv[271]|giv|giv[277]	coref|coref	33-20[292_277]|33-20[292_277]
32-13	4486-4493	glycine	event[271]|substance|abstract[277]	giv[271]|giv|giv[277]	coref	32-23
32-14	4494-4503	excretion	event[271]|abstract[277]	giv[271]|giv[277]	_	_
32-15	4504-4508	were	_	_	_	_
32-16	4509-4513	more	_	_	_	_
32-17	4514-4524	pronounced	_	_	_	_
32-18	4525-4527	in	_	_	_	_
32-19	4528-4536	response	abstract	giv	coref	36-23[324_0]
32-20	4537-4539	to	_	_	_	_
32-21	4540-4555	supplementation	abstract[279]	giv[279]	coref	36-27[328_279]
32-22	4556-4560	with	abstract[279]	giv[279]	_	_
32-23	4561-4568	glycine	abstract[279]|substance|substance[281]	giv[279]|giv|giv[281]	coref|coref|coref|coref	32-28[283_0]|36-25[326_0]|32-28[283_0]|36-25[326_0]
32-24	4569-4572	and	abstract[279]|substance[281]	giv[279]|giv[281]	_	_
32-25	4573-4583	tryptophan	abstract[279]|substance[281]|substance[282]	giv[279]|giv[281]|giv[282]	coref	33-13[0_282]
32-26	4584-4588	than	abstract[279]|substance[281]|substance[282]	giv[279]|giv[281]|giv[282]	_	_
32-27	4589-4593	with	abstract[279]|substance[281]|substance[282]	giv[279]|giv[281]|giv[282]	_	_
32-28	4594-4601	glycine	abstract[279]|substance[281]|substance[282]|substance[283]	giv[279]|giv[281]|giv[282]|giv[283]	coref	33-18[289_283]
32-29	4602-4607	alone	abstract[279]|substance[281]|substance[282]|substance[283]	giv[279]|giv[281]|giv[282]|giv[283]	_	_
32-30	4608-4609	.	_	_	_	_

#Text=Further studies are required to clarify the mechanism underlying the contribution of tryptophan to the effects of glycine on uric acid excretion .
33-1	4610-4617	Further	abstract[284]	giv[284]	coref	36-1[318_284]
33-2	4618-4625	studies	abstract[284]	giv[284]	_	_
33-3	4626-4629	are	_	_	_	_
33-4	4630-4638	required	_	_	_	_
33-5	4639-4641	to	_	_	_	_
33-6	4642-4649	clarify	_	_	_	_
33-7	4650-4653	the	abstract[285]	new[285]	_	_
33-8	4654-4663	mechanism	abstract[285]	new[285]	_	_
33-9	4664-4674	underlying	_	_	_	_
33-10	4675-4678	the	abstract[286]	new[286]	_	_
33-11	4679-4691	contribution	abstract[286]	new[286]	_	_
33-12	4692-4694	of	abstract[286]	new[286]	_	_
33-13	4695-4705	tryptophan	abstract[286]|substance	new[286]|giv	coref	34-48
33-14	4706-4708	to	_	_	_	_
33-15	4709-4712	the	abstract[288]	new[288]	_	_
33-16	4713-4720	effects	abstract[288]	new[288]	_	_
33-17	4721-4723	of	abstract[288]	new[288]	_	_
33-18	4724-4731	glycine	abstract[288]|substance[289]	new[288]|giv[289]	coref	34-43[305_289]
33-19	4732-4734	on	abstract[288]|substance[289]	new[288]|giv[289]	_	_
33-20	4735-4739	uric	abstract[288]|substance[289]|abstract|abstract[292]	new[288]|giv[289]|giv|giv[292]	coref|coref	35-20|35-20
33-21	4740-4744	acid	abstract[288]|substance[289]|substance|abstract[292]	new[288]|giv[289]|giv|giv[292]	coref	35-21
33-22	4745-4754	excretion	abstract[288]|substance[289]|abstract[292]	new[288]|giv[289]|giv[292]	_	_
33-23	4755-4756	.	_	_	_	_

#Text=Among the limitations in the current clinical study , the modest sample size ( n = 16 ) might have reduced the statistical power and increased the risk of type II error , particularly regarding the statistical differences in multiple comparisons between the glycine and glycine + tryptophan groups .
34-1	4757-4762	Among	_	_	_	_
34-2	4763-4766	the	abstract[293]	new[293]	_	_
34-3	4767-4778	limitations	abstract[293]	new[293]	_	_
34-4	4779-4781	in	abstract[293]	new[293]	_	_
34-5	4782-4785	the	abstract[293]|event[294]	new[293]|giv[294]	coref	35-3[309_294]
34-6	4786-4793	current	abstract[293]|event[294]	new[293]|giv[294]	_	_
34-7	4794-4802	clinical	abstract[293]|event[294]	new[293]|giv[294]	_	_
34-8	4803-4808	study	abstract[293]|event[294]	new[293]|giv[294]	_	_
34-9	4809-4810	,	_	_	_	_
34-10	4811-4814	the	quantity[296]	new[296]	_	_
34-11	4815-4821	modest	quantity[296]	new[296]	_	_
34-12	4822-4828	sample	object|quantity[296]	new|new[296]	_	_
34-13	4829-4833	size	quantity[296]	new[296]	_	_
34-14	4834-4835	(	_	_	_	_
34-15	4836-4837	n	quantity	new	_	_
34-16	4838-4839	=	_	_	_	_
34-17	4840-4842	16	quantity	new	_	_
34-18	4843-4844	)	_	_	_	_
34-19	4845-4850	might	_	_	_	_
34-20	4851-4855	have	_	_	_	_
34-21	4856-4863	reduced	_	_	_	_
34-22	4864-4867	the	abstract[299]	new[299]	_	_
34-23	4868-4879	statistical	abstract[299]	new[299]	_	_
34-24	4880-4885	power	abstract[299]	new[299]	_	_
34-25	4886-4889	and	_	_	_	_
34-26	4890-4899	increased	_	_	_	_
34-27	4900-4903	the	abstract[300]	new[300]	_	_
34-28	4904-4908	risk	abstract[300]	new[300]	_	_
34-29	4909-4911	of	abstract[300]	new[300]	_	_
34-30	4912-4916	type	abstract[300]|abstract	new[300]|new	appos	34-31[302_0]
34-31	4917-4919	II	abstract[302]	giv[302]	_	_
34-32	4920-4925	error	abstract[302]	giv[302]	_	_
34-33	4926-4927	,	_	_	_	_
34-34	4928-4940	particularly	_	_	_	_
34-35	4941-4950	regarding	_	_	_	_
34-36	4951-4954	the	abstract[303]	new[303]	coref	35-16[313_303]
34-37	4955-4966	statistical	abstract[303]	new[303]	_	_
34-38	4967-4978	differences	abstract[303]	new[303]	_	_
34-39	4979-4981	in	abstract[303]	new[303]	_	_
34-40	4982-4990	multiple	abstract[303]|abstract[304]	new[303]|new[304]	_	_
34-41	4991-5002	comparisons	abstract[303]|abstract[304]	new[303]|new[304]	_	_
34-42	5003-5010	between	abstract[303]|abstract[304]	new[303]|new[304]	_	_
34-43	5011-5014	the	abstract[303]|abstract[304]|substance[305]	new[303]|new[304]|giv[305]	coref	34-46[0_305]
34-44	5015-5022	glycine	abstract[303]|abstract[304]|substance[305]	new[303]|new[304]|giv[305]	_	_
34-45	5023-5026	and	abstract[303]|abstract[304]	new[303]|new[304]	_	_
34-46	5027-5034	glycine	abstract[303]|abstract[304]|substance	new[303]|new[304]|giv	coref	36-25
34-47	5035-5036	+	abstract[303]|abstract[304]	new[303]|new[304]	_	_
34-48	5037-5047	tryptophan	abstract[303]|abstract[304]|substance|person[308]	new[303]|new[304]|giv|new[308]	coref|coref	36-27|36-27
34-49	5048-5054	groups	abstract[303]|abstract[304]|person[308]	new[303]|new[304]|new[308]	_	_
34-50	5055-5056	.	_	_	_	_

#Text=Furthermore , the current study included only male subjects because of the known effects of sex differences on serum uric acid levels .
35-1	5057-5068	Furthermore	_	_	_	_
35-2	5069-5070	,	_	_	_	_
35-3	5071-5074	the	event[309]	giv[309]	_	_
35-4	5075-5082	current	event[309]	giv[309]	_	_
35-5	5083-5088	study	event[309]	giv[309]	_	_
35-6	5089-5097	included	_	_	_	_
35-7	5098-5102	only	abstract[310]	new[310]	_	_
35-8	5103-5107	male	abstract[310]	new[310]	_	_
35-9	5108-5116	subjects	abstract[310]	new[310]	_	_
35-10	5117-5124	because	abstract[310]	new[310]	_	_
35-11	5125-5127	of	abstract[310]	new[310]	_	_
35-12	5128-5131	the	abstract[310]|abstract[311]	new[310]|new[311]	_	_
35-13	5132-5137	known	abstract[310]|abstract[311]	new[310]|new[311]	_	_
35-14	5138-5145	effects	abstract[310]|abstract[311]	new[310]|new[311]	_	_
35-15	5146-5148	of	abstract[310]|abstract[311]	new[310]|new[311]	_	_
35-16	5149-5152	sex	abstract[310]|abstract[311]|event|abstract[313]	new[310]|new[311]|new|giv[313]	coref|coref	36-15[321_313]|36-15[321_313]
35-17	5153-5164	differences	abstract[310]|abstract[311]|abstract[313]	new[310]|new[311]|giv[313]	_	_
35-18	5165-5167	on	abstract[310]|abstract[311]|abstract[313]	new[310]|new[311]|giv[313]	_	_
35-19	5168-5173	serum	abstract[310]|abstract[311]|abstract[313]|abstract|abstract[317]	new[310]|new[311]|giv[313]|giv|giv[317]	_	_
35-20	5174-5178	uric	abstract[310]|abstract[311]|abstract[313]|abstract|abstract[317]	new[310]|new[311]|giv[313]|giv|giv[317]	_	_
35-21	5179-5183	acid	abstract[310]|abstract[311]|abstract[313]|substance|abstract[317]	new[310]|new[311]|giv[313]|giv|giv[317]	_	_
35-22	5184-5190	levels	abstract[310]|abstract[311]|abstract[313]|abstract[317]	new[310]|new[311]|giv[313]|giv[317]	_	_
35-23	5191-5192	.	_	_	_	_

#Text=Further studies are therefore needed , although our preliminary findings suggested that there were no effective differences between males and females in response to glycine and tryptophan supplementation ( data not shown ) .
36-1	5193-5200	Further	abstract[318]	giv[318]	_	_
36-2	5201-5208	studies	abstract[318]	giv[318]	_	_
36-3	5209-5212	are	_	_	_	_
36-4	5213-5222	therefore	_	_	_	_
36-5	5223-5229	needed	_	_	_	_
36-6	5230-5231	,	_	_	_	_
36-7	5232-5240	although	_	_	_	_
36-8	5241-5244	our	person|abstract[320]	acc|new[320]	_	_
36-9	5245-5256	preliminary	abstract[320]	new[320]	_	_
36-10	5257-5265	findings	abstract[320]	new[320]	_	_
36-11	5266-5275	suggested	_	_	_	_
36-12	5276-5280	that	_	_	_	_
36-13	5281-5286	there	_	_	_	_
36-14	5287-5291	were	_	_	_	_
36-15	5292-5294	no	abstract[321]	giv[321]	_	_
36-16	5295-5304	effective	abstract[321]	giv[321]	_	_
36-17	5305-5316	differences	abstract[321]	giv[321]	_	_
36-18	5317-5324	between	abstract[321]	giv[321]	_	_
36-19	5325-5330	males	abstract[321]|person	giv[321]|new	_	_
36-20	5331-5334	and	abstract[321]	giv[321]	_	_
36-21	5335-5342	females	abstract[321]|person[323]	giv[321]|new[323]	_	_
36-22	5343-5345	in	abstract[321]|person[323]	giv[321]|new[323]	_	_
36-23	5346-5354	response	abstract[321]|person[323]|abstract[324]	giv[321]|new[323]|giv[324]	_	_
36-24	5355-5357	to	abstract[321]|person[323]|abstract[324]	giv[321]|new[323]|giv[324]	_	_
36-25	5358-5365	glycine	abstract[321]|person[323]|abstract[324]|substance|substance[326]	giv[321]|new[323]|giv[324]|giv|giv[326]	_	_
36-26	5366-5369	and	abstract[321]|person[323]|abstract[324]|substance[326]	giv[321]|new[323]|giv[324]|giv[326]	_	_
36-27	5370-5380	tryptophan	abstract[321]|person[323]|abstract[324]|substance[326]|substance|abstract[328]	giv[321]|new[323]|giv[324]|giv[326]|giv|giv[328]	_	_
36-28	5381-5396	supplementation	abstract[321]|person[323]|abstract[324]|substance[326]|abstract[328]	giv[321]|new[323]|giv[324]|giv[326]|giv[328]	_	_
36-29	5397-5398	(	_	_	_	_
36-30	5399-5403	data	abstract	new	_	_
36-31	5404-5407	not	_	_	_	_
36-32	5408-5413	shown	_	_	_	_
36-33	5414-5415	)	_	_	_	_
36-34	5416-5417	.	_	_	_	_
